Partnerships & Mergers

The partnership introduces a new model of care that combines advanced remote monitoring, post-discharge support, and hospital-at-home services, allowing patients to remain connected to healthcare professionals throughout their recovery journey.

The plan targets key pillars of outbreak control, including emergency coordination, disease surveillance, laboratory diagnostics, infection prevention and control, and clinical case management.

Under the new framework, Arcera Life Sciences will collaborate with M42 to harness genomics data and explore disease prevalence patterns across targeted genetic and rare conditions.

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

Through this arrangement, Pfizer aims to accelerate the identification and design of new therapeutic candidates, particularly in areas where traditional research methods have faced limitations.

The innovation aims to enhance fluid drainage, speed up recovery, and potentially reduce the need for additional corrective procedures.

Under the agreement, students and university staff will gain access to confidential digital psychological support sessions delivered through the Arab Therapy platform.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.

The project is supported by the Ministry of Health and Social Protection together with the National Health Institute (Instituto Nacional de Salud), which will coordinate regulatory oversight and public health integration.

Researchers aim to assess the reliability of p-Tau217 in identifying early Alzheimer’s pathology and evaluate its potential as a scalable tool for long-term monitoring.